MET

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

Retrieved on: 
Friday, April 5, 2024
IOV, Tao, Medicine, Savolitinib, VEGFR, Immunotherapy, Patient, MMAE, ERK, Relapse, Neoplasm, University, Huachung University, Cisplatin, Lymphoid leukemia, Lymphoma, Chongqing Medical University, Cholangiocarcinoma, Tyrosine-protein kinase SYK, Classification, Efficacy, MET, ADC, Cardiotoxicity, Nanjing Medical University, Non-receptor tyrosine kinase, Safety, Ferroptosis, Macrophage, Pancreatic cancer, Dual role, National Taiwan University Hospital, GPR34, Oncology, Guangzhou Medical University, MD Anderson Cancer Center, Daratumumab, HCM, NPM1, MLL, 301 Hospital, Acute leukemia, Pharmaceutical industry

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.

Key Points: 
  • HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.
  • Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia.
  • Compared with five other menin inhibitors in clinical development, HMPL-506 showed the stronger inhibitory potency in MLL-rearranged and NPM1 mutant leukemia cell line models.
  • Furthermore, HMPL-506 in combination with azacytidine, venetoclax or gilteritinib synergistically improved the anti-tumor effect against MLL-rearranged leukemias both in vitro and in vivo.

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
APLM, NSCLC, New Drug Application, Patient, NDA, Lung cancer, MET, GCN, FDA, Met, Food, Pharmaceutical industry

ET

Key Points: 
  • ET
    FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) --  Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the full year ended December 31, 2023, and highlighted progress of its pipeline.
  • As a result, Apollomics believes that its current capital resources will fund planned operations through the first quarter of 2025.
  • Dr. Plunkett brings to Apollomics over 25 years of strategic and financial experience within the biopharmaceutical sector, including extensive fundraising and corporate development expertise.
  • In March 2023, the Company raised $23.7 million in a private placement in public equity (PIPE) financing, before transaction expenses.

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Retrieved on: 
Thursday, March 28, 2024
OS, Savolitinib, Conference, NMPA, AstraZeneca, NSCLC, Grade 3, DCR, New Drug Application, WCLC, Patient, Neoplasm, Cerebral edema, Gamma-glutamyltransferase, MET, Lung cancer, HKEX, Dor, Safety, PFS, Pharmaceutical industry

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the supplemental New Drug Application (“sNDA”) for savolitinib, in adult patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) with mesenchymal epithelial transition factor (“MET”) exon 14 skipping alteration, has been accepted for review by the China National Medical Products Administration (NMPA). If approved, the new label indication for savolitinib will be expanded to include treatment-naïve patients in China.

Key Points: 
  • Savolitinib was previously granted conditional approval in China for the treatment of patients with NSCLC with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy.
  • Savolitinib was launched and is marketed under the brand name ORPATHYS® by our partner, AstraZeneca for this patient population, representing the first selective MET inhibitor approved in China.
  • More than a third of the world’s lung cancer patients are in China and, among those with NSCLC globally, approximately 2-3% have tumors with MET exon 14 skipping alterations.
  • The data from this study provide confirmatory evidence for savolitinib as a targeted treatment option for treatment-naïve or previously treated patients with MET exon 14 skipping alteration NSCLC.

MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Survival, Maat, Fatty acid, Patient, SCFA, Cancer, AACR, MET, Pharmaceutical industry

MaaT034, the first product from MaaT Pharma’s MET-C platform is a ground-breaking full ecosystem synthetic microbiota product, developed in combination with immune checkpoint inhibitors to improve treatment efficacy in large market solid tumor indications.

Key Points: 
  • MaaT034, the first product from MaaT Pharma’s MET-C platform is a ground-breaking full ecosystem synthetic microbiota product, developed in combination with immune checkpoint inhibitors to improve treatment efficacy in large market solid tumor indications.
  • The MET-C platform enables MaaT Pharma to produce microbiome therapies at a large-scale to meet the needs of larger market indications.
  • The data published represents significant advancements in understanding the mechanism of action (MoA) of co-cultured microbiome therapies developed by MaaT Pharma, marking a major step towards clinical evaluation.
  • These findings support the role of MaaT034 in gut barrier repair and in T cell reactivation either in combination with Nivolumab (anti-PD1) or with Atezolizumab (anti-PD-L1).

MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont/ Groupe Société Générale

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Research report, Patient, Target price, Target, MET, Survival, Cancer, Kepler Cheuvreux, Fine chemical

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, announces the initiation of coverage of its stock by Gilbert Dupont.

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, announces the initiation of coverage of its stock by Gilbert Dupont.
  • With a research report named “Echec et MaaT”, Gilbert Dupont / Groupe Société Générale initiated coverage of MaaT Pharma on April 4th, 2024 with a Buy recommendation and a Target Price of 16 Euros.
  • This new coverage strengthens the visibility of MaaT Pharma among French and international institutional investors and adds to the ongoing coverage by the brokerage firms, Kepler Cheuvreux, KBC Securities, Kempen and Portzamparc/Groupe BNP Paribas.

MetLife Named to Fortune Magazine’s 2024 List of the 100 Best Companies to Work For®

Retrieved on: 
Thursday, April 4, 2024
Professional Services, Insurance, Finance, Culture, Organization, MetLife, MET, Workplace

MetLife, Inc. (NYSE: MET) today announced it is among Fortune magazine’s 100 Best Companies to Work For® in 2024.

Key Points: 
  • MetLife, Inc. (NYSE: MET) today announced it is among Fortune magazine’s 100 Best Companies to Work For® in 2024.
  • MetLife is one of four insurance companies on the list.
  • “MetLife’s inclusion on Fortune’s list is based on feedback from those who know our company best – our people,” said MetLife President and CEO Michel Khalaf.
  • MetLife has been certified by Great Place to Work in Brazil, Chile, China, Colombia, Cyprus, India, Lebanon, Mexico, Romania, the United States and Uruguay.

MetLife to Hold Conference Call for First Quarter 2024 Results

Retrieved on: 
Wednesday, April 3, 2024
Professional Services, Insurance, Human Resources, Finance, Asset Management, Consulting, Telephone, Internet, MET, News, MetLife

MetLife, Inc. (NYSE: MET) today announced that it will hold its first quarter 2024 earnings conference call and audio webcast on Thursday, May 2, 2024, from 9-10 a.m. (ET).

Key Points: 
  • MetLife, Inc. (NYSE: MET) today announced that it will hold its first quarter 2024 earnings conference call and audio webcast on Thursday, May 2, 2024, from 9-10 a.m. (ET).
  • The call will follow MetLife’s issuance of its first quarter 2024 earnings news release and First Quarter 2024 Financial Supplement on Wednesday, May 1, 2024, after the market closes.
  • The news release and First Quarter 2024 Financial Supplement will also be available on the MetLife Investor Relations web page ( https://investor.metlife.com ).
  • To listen to the conference call via the internet, click the link to the webcast on the MetLife Investor Relations web page ( https://investor.metlife.com ).

MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Pharmaceutical, Finance, Oncology, Health, FDA, Professional Services, Clinical Trials, AP-HP, Bone marrow, Survival, Immunotherapy, Patient, Innovation, IND, Ipilimumab, European Medicines Agency, Therapy, Artificial intelligence, Charcot disease, ASH, EMA, Head, MET, Investigational New Drug, Nivolumab, Safety, SITC, Microbiome, Food, ODD, Development, Acceleration, Maat, ARES, Cancer, AACR, DSMB, Haematopoietic system, Annual general meeting, OS, EUR, Physician, CIMON, CGMP, EAP, EBMT, ICI, Society, Randomized controlled trial, Symantec Endpoint Protection, Pharmaceutical industry

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, today reported the full-year 2023 annual results and provided a business overview.

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, today reported the full-year 2023 annual results and provided a business overview.
  • In December 2023 , the Company presented positive results from the Early Access Program (EAP) in Europe involving 111 patients with aGvHD treated with MaaT013, at the 2023 American Society of Hematology (ASH) Annual Meeting.
  • In April 2023 , data from the Phase 1b study (CIMON) with MaaT033, previously communicated during the 64th annual ASH meeting, were also presented at the EBMT 2023 conference.
  • During 2023 and Q1 2024, MaaT Pharma reinforced its board of directors, executive team, and key functions:
    Karim Dabbagh as Chairman and Nadia Kamal as Director, both independent.

MetLife Recognized as 2024 ENERGY STAR® Partner of the Year for Sixth Consecutive Year

Retrieved on: 
Tuesday, March 26, 2024
Environment, Insurance, Construction & Property, Finance, Professional Services, Building Systems, Alternative Energy, Sustainability, Energy, Real estate, Communication, Partnership, MetLife, Organization, EPA, MET, MIM, Partner, Data management

MetLife, Inc. (NYSE: MET) today announced that it has received the 2024 ENERGY STAR® Partner of the Year Sustained Excellence Award from the U.S. Environmental Protection Agency (EPA).

Key Points: 
  • MetLife, Inc. (NYSE: MET) today announced that it has received the 2024 ENERGY STAR® Partner of the Year Sustained Excellence Award from the U.S. Environmental Protection Agency (EPA).
  • MetLife has been honored as an ENERGY STAR Partner of the Year recipient for six consecutive years and continues to partner with ENERGY STAR on adopting energy-efficient practices and tracking data across all owned and managed properties.
  • In addition to recertifying 32 existing certifications across MetLife and MetLife Investment Management (MIM) portfolios in 2023, MetLife received new ENERGY STAR Building Certifications for two buildings and MIM certified four new buildings.
  • ENERGY STAR Partner of the Year is the highest level of EPA recognition for corporate and asset manager’s energy management programs.

MaaT Pharma Strengthens Executive Team Appointing Jonathan Chriqui as Chief Business Officer

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Neurology, Growth, Survival, Doctor of Pharmacy, Microbiota, Maat, Patient, Ipsen, Cancer, MET, Pharmaceutical industry

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announced the appointment of Jonathan Chriqui, PharmD, as Chief Business Officer and member of the executive management team.

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announced the appointment of Jonathan Chriqui, PharmD, as Chief Business Officer and member of the executive management team.
  • Jonathan Chriqui will be responsible for MaaT Pharma’s business development and partnering strategies along with promoting MaaT Pharma's innovations within the microbiome industry.
  • MaaT Pharma is now poised to propel its lead asset, MaaT013, into the next phase of development and prepare for its commercial launch,” said Hervé Affagard, Chief Executive Officer and co-founder of MaaT Pharma.
  • I look forward to contributing to the advancement of MaaT013 towards the market and supporting the company’s mission of providing new treatment options for patients with cancer,” shared Jonathan Chriqui, Chief Business Officer at MaaT Pharma.